1. Home
  2. SAGE
  3. SAGE News

Latest Sage Therapeutics Inc. (SAGE) News on June 18, 2025

H.C. Wainwright sees potential competition for Sage from Biogen
SAGE

TipRanks

8 hours ago

H.C. Wainwright sees potential competition for Sage from Biogen

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
SAGE

Zacks

a day ago

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?
SAGE

Zacks

a day ago

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus
SAGE

TipRanks

a day ago

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus

Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics
SAGE

Investor's Business Daily

2 days ago

Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know.
SAGE

Barrons.com

2 days ago

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know.

Supernus makes depression drug play with $795m Sage buyout
SAGE

Pharmaceutical Technology

2 days ago

Supernus makes depression drug play with $795m Sage buyout

SAGE

MT Newswires

2 days ago

Sector Update: Health Care Stocks Flat to Higher Premarket Monday

Sage, following Setbacks, to sell to Supernus for $561M
SAGE

BioPharma Dive

2 days ago

Sage, following Setbacks, to sell to Supernus for $561M

SAGE

MT Newswires

2 days ago

Supernus Pharmaceuticals to Acquire Sage for Up to $795 Million in Cash

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
SAGE

GlobeNewswire

2 days ago

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

Ulta Stock Jumps as Beauty Product Spending Continues
SAGE

Investopedia

19 days ago

Ulta Stock Jumps as Beauty Product Spending Continues

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy
SAGE

GlobeNewswire

19 days ago

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy
SAGE

GlobeNewswire

19 days ago

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy

Northrop Grumman Raises $1 Billion Via Debt
SAGE

Benzinga

19 days ago

Northrop Grumman Raises $1 Billion Via Debt

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy
SAGE

GlobeNewswire

19 days ago

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy

SAGE

Newsfile

19 days ago

Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast
SAGE

GlobeNewswire

19 days ago

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast

The York Water Company Files a Rate Request Based on $145 Million in Investment
SAGE

GlobeNewswire

19 days ago

The York Water Company Files a Rate Request Based on $145 Million in Investment

Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?
SAGE

Zacks

20 days ago

Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y
SAGE

Zacks

2 months ago

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y

Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: Strong Demand for ZURZUVAE and ...
SAGE

GuruFocus.com

2 months ago

Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: Strong Demand for ZURZUVAE and ...

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates
SAGE

Zacks

2 months ago

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates

Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates
SAGE

Business Wire

2 months ago

Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
SAGE

Zacks

2 months ago

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
SAGE

Zacks

2 months ago

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025
SAGE

Business Wire

2 months ago

Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025

Sage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue?
SAGE

Zacks

3 months ago

Sage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue?

Sage Therapeutics Announces R&D Leadership Transition
SAGE

Business Wire

4 months ago

Sage Therapeutics Announces R&D Leadership Transition

Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025
SAGE

Insider Monkey

4 months ago

Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025

Is Sage Therapeutics, Inc. (SAGE) the Best Small-Cap Growth Stock to Buy Now?
SAGE

Insider Monkey

4 months ago

Is Sage Therapeutics, Inc. (SAGE) the Best Small-Cap Growth Stock to Buy Now?

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank
SAGE

TipRanks

4 months ago

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank

Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
SAGE

Zacks

4 months ago

Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y

SAGE

Thomson Reuters StreetEvents

4 months ago

Q4 2024 SAGE Therapeutics Inc Earnings Call

Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ...
SAGE

GuruFocus.com

4 months ago

Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ...

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates
SAGE

Zacks

4 months ago

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates

Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates
SAGE

Business Wire

4 months ago

Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for
SAGE

Zacks

4 months ago

Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
SAGE

Zacks

5 months ago

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
SAGE

Zacks

5 months ago

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
SAGE

Business Wire

5 months ago

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
SAGE

Zacks

5 months ago

SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up

Sage rejects Biogen’s $469m takeover bid
SAGE

Pharmaceutical Technology

5 months ago

Sage rejects Biogen’s $469m takeover bid

SAGE

MT Newswires

5 months ago

Sector Update: Health Care Stocks Gain Monday Afternoon

SAGE

MT Newswires

5 months ago

Update: Sage Therapeutics Board Rejects Biogen's Unsolicited Acquisition Bid

SAGE

MT Newswires

5 months ago

SAGE Therapeutics Board Rejects Biogen's Unsolicited Acquisition Bid

Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
SAGE

Reuters

5 months ago

Sage rejects Biogen's $469 million takeover offer, says offer undervalues company

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
SAGE

Business Wire

5 months ago

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
SAGE

Zacks

5 months ago

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK

Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist
SAGE

TipRanks

5 months ago

Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist

Biogen bid for Sage does not change narrative, says BMO Capital
SAGE

TipRanks

5 months ago

Biogen bid for Sage does not change narrative, says BMO Capital

Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?
SAGE

Zacks

5 months ago

Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?

Biogen proposes acquisition of partner Sage Therapeutics
SAGE

Pharmaceutical Technology

5 months ago

Biogen proposes acquisition of partner Sage Therapeutics

Biogen Offers to Buy Remaining Stake in Sage Therapeutics
SAGE

Zacks

5 months ago

Biogen Offers to Buy Remaining Stake in Sage Therapeutics

Biogen Wants to Buy Its Partner Sage for Almost No Premium
SAGE

Barrons.com

5 months ago

Biogen Wants to Buy Its Partner Sage for Almost No Premium

Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid
SAGE

Investopedia

5 months ago

Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
SAGE

Benzinga

5 months ago

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen
SAGE

Barrons.com

5 months ago

Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen

Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street
SAGE

BioPharma Dive

5 months ago

Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street

SAGE

MT Newswires

5 months ago

SAGE Therapeutics Receives Unsolicited $7.22 Per Share Acquisition Proposal From Biogen

Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference
SAGE

Business Wire

5 months ago

Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
SAGE

Business Wire

5 months ago

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

Biogen proposes to buy remaining stake in Sage in $442 million deal
SAGE

Reuters

5 months ago

Biogen proposes to buy remaining stake in Sage in $442 million deal

Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025
SAGE

Business Wire

5 months ago

Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

Wall Street Analysts Believe Sage Therapeutics (SAGE) Could Rally 42.02%: Here's is How to Trade
SAGE

Zacks

5 months ago

Wall Street Analysts Believe Sage Therapeutics (SAGE) Could Rally 42.02%: Here's is How to Trade

Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
SAGE

Zacks

6 months ago

Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?

Sage Therapeutics price target lowered to $6 from $10 at Stifel
SAGE

TipRanks

6 months ago

Sage Therapeutics price target lowered to $6 from $10 at Stifel

Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
SAGE

Business Wire

7 months ago

Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Sage Therapeutics price target lowered to $4 from $7 at BofA
SAGE

TipRanks

7 months ago

Sage Therapeutics price target lowered to $4 from $7 at BofA

SAGE

MT Newswires

7 months ago

Sage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC Says

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
SAGE

Zacks

7 months ago

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More

Sage ends dalzanemdor development following Phase II trial failure
SAGE

Clinical Trials Arena

7 months ago

Sage ends dalzanemdor development following Phase II trial failure

SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
SAGE

Zacks

7 months ago

SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
SAGE

Benzinga

7 months ago

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder

SAGE

MT Newswires

7 months ago

Wedbush Cuts Price Target on SAGE Therapeutics to $4 From $7, Maintains Neutral Rating

SAGE

MT Newswires

7 months ago

SAGE Therapeutics' Study of Dalzanemdor Fails to Meet Primary, Secondary Endpoints

Sage’s string of research failures continues
SAGE

BioPharma Dive

7 months ago

Sage’s string of research failures continues

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
SAGE

Business Wire

7 months ago

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease

Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler
SAGE

TipRanks

8 months ago

Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler

SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
SAGE

Zacks

8 months ago

SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

Biogen, Sage admit a defeat in major depression
SAGE

BioPharma Dive

8 months ago

Biogen, Sage admit a defeat in major depression

Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
SAGE

GuruFocus.com

8 months ago

Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
SAGE

Zacks

8 months ago

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
SAGE

Business Wire

8 months ago

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
SAGE

Zacks

8 months ago

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
SAGE

Zacks

8 months ago

Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

State Street Corp's Strategic Acquisition of Sage Therapeutics Shares
SAGE

GuruFocus.com

8 months ago

State Street Corp's Strategic Acquisition of Sage Therapeutics Shares

Sage Therapeutics to Reduce Workforce by 33%, Stock Down
SAGE

Zacks

8 months ago

Sage Therapeutics to Reduce Workforce by 33%, Stock Down

Sage lays off 55% of R&D workforce and refocuses pipeline
SAGE

Pharmaceutical Technology

8 months ago

Sage lays off 55% of R&D workforce and refocuses pipeline

Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline
SAGE

GuruFocus.com

8 months ago

Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline

After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
SAGE

Benzinga

8 months ago

After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce

Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard.
SAGE

Barrons.com

8 months ago

Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard.

Sage to cut one-third of workforce, streamline drug pipeline
SAGE

BioPharma Dive

8 months ago

Sage to cut one-third of workforce, streamline drug pipeline

SAGE

MT Newswires

8 months ago

SAGE Therapeutics to Cut Workforce by 33%, or 165 Workers, in Reorganization

Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
SAGE

Business Wire

8 months ago

Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio

Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
SAGE

Business Wire

8 months ago

Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Sage Therapeutics price target lowered to $8 from $9 at Wedbush
SAGE

TipRanks

8 months ago

Sage Therapeutics price target lowered to $8 from $9 at Wedbush

SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study
SAGE

Zacks

8 months ago

SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study

Sage Therapeutics Reports Disappointing Study Results for Alzheimer’s Treatment
SAGE

Barrons.com

8 months ago

Sage Therapeutics Reports Disappointing Study Results for Alzheimer’s Treatment

After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
SAGE

Benzinga

8 months ago

After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study

Share on Social Networks: